AstraZeneca discontinues lung cancer trial of volrustomig

Investing.com•Mon, Aug 17, 2026, 06:42 AM•2 min read

Developing story — details emerging. Check the source link for the latest updates.

Source: [Investing.com](https://www.investing.com/news/company-news/astrazeneca-discontinues-lung-cancer-trial-of-volrustomig-93CH-4862208)

📰 Read Full Story

This is an aggregated headline summary. For the complete report, visit the original publisher.

Continue Reading at Investing.com ↗

#finance #astrazeneca #discontinues #lung #cancer #trial #volrustomig

More Headlines

FinanceSeeking Alpha• 11m ago

Rates Spark: Long-End Risks, ECB Conviction And U.K. Data Tests

Developing story — details emerging. Check the source link for the latest updates.

FinanceInvesting.com• 21m ago

Piper Sandler initiates Dave stock coverage with overweight rating

Developing story — details emerging. Check the source link for the latest updates.

FinanceSeeking Alpha• 23m ago

Williams: Play The New Growth Cycle For Natural Gas

Developing story — details emerging. Check the source link for the latest updates.

FinanceInvesting.com• 24m ago

ULTRA Web3 Festival Concludes Landmark Kuala Lumpur Gathering, Announces Global Partnership with GWDC 2026 Korea

Developing story — details emerging. Check the source link for the latest updates.

FinanceInvesting.com• 24m ago

SKF India Q2 FY27 slides: 27% revenue growth, margins stabilize

Developing story — details emerging. Check the source link for the latest updates.

FinanceBloomberg Markets• 25m ago

China Reserve Gauge Hits 12-Year High, Smoothing Yuan Rise

China’s key gauge of reserve assets saw its biggest quarterly rise in more than 12 years as authorities absorbed heavy foreign currency inflows, a move that helps smooth the pace of the yuan’s gains, according to analysts.